The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation

On October 24, 2019, a marketing authorization valid through the European Union (EU) was issued for gilteritinib monotherapy for adult patients who have relapsed or refractory acute myeloid leukemia (AML) with an Fms‐like tyrosine kinase 3 (FLT3) mutation. Gilteritinib inhibits FLT3 receptor signali...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Tzogani, Kyriaki, Røshol, Hilde, Olsen, Helga Haugom, Aas, Ida B., Dalhus, Marianne Løiten, Håkonsen, Gro Dahlseng, Nilssen, Laila Sortvik, Lindberg, Vibeke, Økvist, Mats, Bolstad, Bjørg, Rogovska, Irēna, Karpova, Natalja, Enzmann, Harald, Gisselbrecht, Christian, Pignatti, Francesco
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2020
Soggetti:
Regulatory Issues: EMA
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356782/
https://ncbi.nlm.nih.gov/pubmed/32154636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0976
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi